HK Inno.N has submitted a marketing authorization application for IN-115314, a canine atopic dermatitis treatment, marking its first step into the veterinary pharmaceutical market. The move signals the company's strategic diversification beyond its core infusion, vaccine, and health & beauty businesses, offering new sourcing opportunities for overseas distributors and clinic buyers in the companion animal health segment.
First veterinary drug candidate
HK Inno.N applied to Korea's Animal and Plant Quarantine Agency for approval of IN-115314, a treatment for canine atopic dermatitis. This is the company's first commercialization attempt in the veterinary drug sector, following Phase 3 clinical trial approval in May 2024. The company established a dedicated animal health task force in Q1 2025, formalizing its organizational commitment to this new business line.
Market opportunity and competitive landscape
Canine atopic dermatitis is a chronic condition requiring long-term management, driving steady demand for effective therapies. Currently, Zoetis' Apoquel (oclacitinib) is the only JAK inhibitor-based treatment approved globally for companion animal atopic dermatitis. IN-115314, developed from HK Inno.N's autoimmune disease pipeline, targets this underserved segment with a novel mechanism.
Diversification across existing businesses
Beyond animal health, HK Inno.N is expanding its infusion business: Q1 2025 infusion sales reached KRW 37.1 billion (USD 28 million), up 10.7% year-on-year, with total parenteral nutrition (TPN) sales growing 16.7%. In vaccines, the company signed a co-promotion agreement with Pfizer Korea for the 2025-2026 season's COVID-19 variant vaccine Comirnaty under Korea's National Immunization Program. Its H&B division launched 'Condition Stick Zero' and a melon soda flavor variant of 'Condition Zero Sparkling', while cosmetics brand 'Be:Wants' entered Olive Young's US online and offline channels in June 2025.
What buyers should watch
For overseas distributors and clinic buyers in the companion animal health space, IN-115314's approval timeline and eventual launch could provide a competitive alternative to existing JAK inhibitor therapies. HK Inno.N's established manufacturing capabilities in infusions and vaccines may also offer cross-selling opportunities for veterinary clinics seeking bundled supply agreements. The company's growing presence in US beauty retail through Be:Wants signals broader international ambitions that could extend to animal health distribution partnerships.
Source: Read the original report | Published: June 17, 2026